Sanofi Consumer Healthcare

Radical Transformation on the Horizon for Sanofi

Earlier this month, Sanofi announced a new strategic vision for its Consumer Healthcare division.  The new head of the division, Julie Van Ongevalle, shared that the company will focus on core brands and categories while pursuing first-in-class Rx-to-OTC switches in the ED and flu categories in the United States. Key components to future growth of Sanofi’s OTC business in the United States are novel Rx-to-OTC switches. The company is entrenched in its work to develop nonprescription versions of Cialis for erectile dysfunction and Tamiflu influenza medication in the States. As of December 2020, Sanofi has more than 16 clinical studies either complete or underway to support applications for OTC marketing of these two medications. Actualuse trials to understand how consumers behave and interact with these medicines will be key factors in the success of the switches. These brands have the potential to be blockbusters, as there are currently no medications for either condition available without a prescription in the United States. Detailed analyses of both of these medications and the likelihood and timing of approval and sales forecasts are included in Kline’s Rx-to-OTC Switch Forecasts study.   Continue reading